Expansion opportunities JRS Pharma has recent and ongoing expansion activity in the United States with a $15M investment to build a new production facility and tank farm in Cedar Rapids, IA, suggesting capacity growth and potential for higher excipient volumes and broader regional coverage.

Innovative coatings The launch of VIVACOAT and VIVACOAT-free titanium dioxide-free ready-to-use coatings indicates a focus on specialized coating solutions, presenting a cross-sell opportunity to customers seeking advanced functional coatings and formulation flexibility.

Alginate line Introduction of VIVAPHARM alginates expands product capabilities for disintegration and pH-controlled release, offering upsell potential to formulators needing tailored disintegration and controlled-release excipients.

Global support With 7 R&D centers, 31 production sites, 25 sales offices, and award-winning customer service, JRS Pharma emphasizes technical support and fast time-to-market, enabling sales teams to position value-added collaborations and shortened development cycles for customers.

Financial scale Revenue in the $100M-$250M range and a sizable employee base position JRS Pharma as a mid-market partner capable of handling larger, long-term contracts with pharmaceutical manufacturers and contract development organizations seeking reliable excipient supply.